Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting

Advanced Drug Delivery Reviews
P C RensenT J van Berkel

Abstract

Lipoproteins are endogenous particles that transport lipids through the blood to various cell types, where they are recognised and taken up via specific receptors. These particles are, therefore, excellent candidates for the targeted delivery of drugs to various tissues. For example, the remnant receptor and the asialoglycoprotein receptor (ASGPr), which are uniquely localised on hepatocytes, recognise chylomicrons and lactosylated high density lipopoteins (HDL), respectively. In addition, tumour cells of various origins overexpress the low density lipoprotein (LDL) receptor that recognises apolipoprotein E (apoE) on small triglyceride-rich particles and apoB-100 on LDL. Being endogenous, lipoproteins are biodegradable, do not trigger immune reactions, and are not recognised by the reticuloendothelial system (RES). However, their endogenous nature also hampers large-scale pharmaceutical application. In the past two decades, various research groups have successfully synthesised recombinant lipoproteins from commercially available natural and synthetic lipids and serum-derived or recombinant apolipoproteins, which closely mimic the metabolic behaviour of their native counterparts in animal models as well as humans. In this paper,...Continue Reading

References

Mar 28, 1975·Science·A J Wicken, K W Knox
Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S T KunitakeJ P Kane
Sep 21, 1991·Lancet·M P GlauserJ Cohen
Jan 1, 1991·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·C BaumbergerJ M Dayer
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S VitolsK Söderberg-Reid
Sep 1, 1990·The Journal of Clinical Investigation·H W HarrisJ H Rapp
Nov 9, 1989·The New England Journal of Medicine·D J Gordon, B M Rifkind
Feb 12, 1986·Biochimica Et Biophysica Acta·R C MaranhaoT G Redgrave
Apr 4, 1986·Science·M S Brown, J L Goldstein
Jan 1, 1986·Annual Review of Biophysics and Biophysical Chemistry·D Atkinson, D M Small
Jan 1, 1986·Methods in Enzymology·A M GottoR J Havel
Jan 1, 1986·Methods in Enzymology·A Jonas
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·T VogelD Kanner
Jun 14, 1985·Biochimica Et Biophysica Acta·T G Redgrave, R C Maranhao
Mar 8, 1980·Lancet·G Rose, M J Shipley
May 8, 1981·Science·M S BrownJ L Goldstein
Jan 1, 1982·Annual Review of Biochemistry·G Ashwell, J Harford
May 24, 1983·Biochimica Et Biophysica Acta·R W Mahley, T L Innerarity
Mar 1, 1980·The Journal of Clinical Investigation·F ShelburneS Quarfordt
Nov 1, 1995·The Journal of Surgical Research·A T CasasJ E Doran
Oct 24, 1995·Proceedings of the National Academy of Sciences of the United States of America·S J De KimpeJ R Vane
Oct 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L FiumeC Argentini
Nov 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·A MiyazakiM Natio

❮ Previous
Next ❯

Citations

Sep 18, 2008·European Biophysics Journal : EBJ·Ruth Prassl, Peter Laggner
Mar 11, 2004·International Journal of Pharmaceutics·Junzo SekiTadanori Mayumi
Aug 2, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Tomoko NakayamaDinah Wy Sah
Oct 22, 2011·Nature Reviews. Drug Discovery·Mark E LobattoWillem J M Mulder
Oct 6, 2011·Anti-cancer Drugs·Meghna TalekarSanjay Garg
Mar 25, 2009·Cancer Cell International·Lian ZuoShaojin You
May 18, 2010·Journal of Lipid Research·Daniel A BricarelloAtul N Parikh
Mar 29, 2014·PloS One·Nicholas O FischerCraig D Blanchette
Dec 21, 2013·Nanomedicine·Qiaoya LinGang Zheng
Mar 31, 2010·Clinical Lipidology·David P CormodeEdward A Fisher
Sep 18, 2012·Advanced Drug Delivery Reviews·Elsa CassetteThomas Pons
Nov 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Gang ZhengJerry D Glickson
May 28, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Xueqing WangQiang Zhang
Apr 18, 2012·Expert Opinion on Drug Delivery·Jia-You Fang, Saleh A Al-Suwayeh
Jan 18, 2008·Journal of Pharmaceutical Sciences·Ales Prokop, Jeffrey M Davidson
Feb 24, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anisha A D'Souza, Padma V Devarajan
Jan 3, 2013·Advanced Drug Delivery Reviews·Fumiyoshi Yamashita, Mitsuru Hashida
Jan 23, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Fatemeh PourgholiMehdi Yousefi
Feb 12, 2015·Langmuir : the ACS Journal of Surfaces and Colloids·Masahiro MizunoMinoru Seki
Jun 28, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Kristen M JaruszewskiKarunya K Kandimalla
Mar 10, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hyungjin KimTatsuya Murakami
Jan 8, 2004·Liver International : Official Journal of the International Association for the Study of the Liver·S ChaïbJ P De Bandt
Apr 28, 2009·Biotechnology and Bioengineering·J Brandon DixonMelody A Swartz
May 15, 2009·The FEBS Journal·Erik HellstrandTommy Cedervall
Oct 30, 2007·ChemMedChem·Felix KratzAndré Warnecke
Jan 29, 2014·Contrast Media & Molecular Imaging·David P CormodeZahi A Fayad
Jun 22, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Xiaoxiao HeZhen Cheng
Feb 19, 2016·ACS Nano·Rui KuaiAnna Schwendeman
Jun 1, 2006·Current Opinion in Colloid & Interface Science·J Bruce GermanAngela M Zivkovic
Sep 6, 2005·International Journal of Pharmaceutics·Annie M Dierling, Zhengrong Cui
Oct 8, 2013·Journal of Drug Targeting·Baolong WangMeiqing Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.